Home-Use Device Safe, Effective for Periorbital Wrinkles

Share this content:
Home-Use Device Safe, Effective for Periorbital Wrinkles
Home-Use Device Safe, Effective for Periorbital Wrinkles

TUESDAY, Dec. 13, 2016 (HealthDay News) -- A home-use device combining radiofrequency and light-emitting diode energies is safe and efficacious for self-treatment of periorbital wrinkles, according to a study published online Dec. 2 in the Journal of Cosmetic Dermatology.

Michael H. Gold, M.D., from the Tennessee Clinical Research Center in Nashville, and colleagues examined the safety, efficacy, and usage compliance of the home-use device using radiofrequency and light-emitting diode energies for self-treatment of periorbital wrinkles. Thirty-three subjects performed 21 treatment sessions on alternate days over a six-week period. Two maintenance treatments were conducted at one and two months following the end of treatment. Results were compared before treatment and three months after treatment, with each subject serving as their own control. The study was completed by 30 subjects.

The researchers observed an average reduction of 1.49 Fitzpatrick scores in blinded, independent photograph assessment of three dermatologists (P < 0.001). Improvement was seen in almost all subjects (downgrade of at least 1 score). There were no reports of unexpected adverse events. All subjects had post-treatment erythema, which disappeared within one hour. Post-treatment edema was detected in some subjects and resolved within 24 hours. There were reports of high satisfaction with device operation, ease of treatments, safety, and wrinkle reduction.

"The Silk'n Home Skin Tightening device offers a safe and effective in-home noninvasive technique to improve the appearance of age-related periorbital wrinkles," the authors write.

One author was employed by Home-Skinovations Ltd., which manufactures the Silk'n Home Skin Tightening device and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »